Cyclerion Therapeutics Inc (CYCN)
3.04
+0.27
(+9.75%)
USD |
NASDAQ |
Apr 25, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 8.239M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -45.48% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 13.26 |
Price to Book Value | 0.7299 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.58% |
Profile
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. |
URL | https://www.cyclerion.com |
Investor Relations URL | N/A |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. |
URL | https://www.cyclerion.com |
Investor Relations URL | N/A |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |